Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
arcticnovartis

  • Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline
  • Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030
  • Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook

/by

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis

  • Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe
  • Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521
/by

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis

  • Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe
  • Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521
/by